Endocrine resistance in breast cancer: New roles for ErbB3 and ErbB4

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Sutherland, Robert L ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; FULVESTRANT; GROWTH INHIBITOR; KI 67 ANTIGEN; NEU DIFFERENTIATION FACTOR; DRUG DERIVATIVE; ESTRADIOL;

BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; EDITORIAL; GENE EXPRESSION; GROWTH STIMULATION; HUMAN; PROTEIN PHOSPHORYLATION; UPREGULATION; FEMALE; METABOLISM; NOTE; BREAST CANCER CELL LINE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL PLASTICITY; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ESTRADIOL; FEMALE; HUMANS; NEUREGULIN-1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3;

EID: 84860390189     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2878     Document Type: Editorial

References (15)

1. Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes ER-positive breast cancer cells to heregulin beta1. Breast Cancer Res 2011, 13:R29. 10.1186/bcr2848, 21396094.
2. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
3. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044. 10.1210/en.2002-220620, 12586780.
4. Revillion F, Pawlowski V, Lhotellier V, Louchez MM, Peyrat JP. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen. Anticancer Res 2003, 23:1455-1460.
5. Bates NP, Hurst HC. An intron 1 enhancer element mediates oestrogeninduced suppression of ERBB2 expression. Oncogene 1997, 15:473-481. 10.1038/sj.onc.1201368, 9242384.
6. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS. ERBB2 regulation by estrogen receptor-Pax2 determines tamoxifen response. Nature 2008, 456:663-666. 10.1038/nature07483, 2920208, 19005469.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354. 10.1038/nrc1609, 15864276.
8. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R. Involvement of heregulin-β in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 1996, 56:3350-3358.
9. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882. 10.1002/ijc.22423, 17266042.
10. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2, de Cremoux P, Stenvang J, Lykkesfeldt AE. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009, 114:263-275. 10.1007/s10549-008-0011-8, 2764248, 18409071.
11. Ghayad SE, Vendrell JA, Larbi SB, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010, 126:545-562. 10.1002/ijc.24750, 19609946.
12. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 2006, 66:7991-7998. 10.1158/0008-5472.CAN-05-4397, 16912174.
13. Hochgr F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 2010, 70:9391-9401. 10.1158/0008-5472.CAN-10-0911, 20861192.
14. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:1979-1987. 10.1158/1078-0432.CCR-09-1823, 20332324.
15. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475. 10.1038/nrc2656, 19536107.